Alexion Pharmaceuticals, Inc. (ALXN): Price and Financial Metrics

Alexion Pharmaceuticals, Inc. (ALXN)

Today's Latest Price: $112.30 USD

0.09 (-0.08%)

Updated Jul 2 4:00pm

Add ALXN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

ALXN Stock Summary

  • ALXN has a market capitalization of $24,785,670,855 -- more than approximately 92.62% of US stocks.
  • Over the past twelve months, ALXN has reported earnings growth of 352.94%, putting it ahead of 96.24% of US stocks in our set.
  • In terms of volatility of its share price, ALXN is more volatile than only 6.58% of stocks we're observing.
  • Stocks that are quantitatively similar to ALXN, based on their financial statements, market capitalization, and price volatility, are KLAC, GRMN, YNDX, BILI, and IQ.
  • Visit ALXN's SEC page to see the company's official filings. To visit the company's web site, go to
ALXN Daily Price Range
ALXN 52-Week Price Range

ALXN Stock Price Chart Technical Analysis Charts

ALXN Price/Volume Stats

Current price $112.30 52-week high $134.84
Prev. close $112.39 52-week low $72.67
Day low $111.72 Volume 1,283,159
Day high $114.49 Avg. volume 2,405,032
50-day MA $108.98 Dividend yield N/A
200-day MA $103.79 Market Cap 24.80B

Alexion Pharmaceuticals, Inc. (ALXN) Company Bio

Alexion Pharmaceuticals a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company was founded in 1992 and is based in Cheshire, Connecticut.

ALXN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

We started the process of determining a valid price forecast for Alexion Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Alexion Pharmaceuticals Inc ranked in the 73th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 236.67%. In terms of the factors that were most noteworthy in this DCF analysis for ALXN, they are:

  • The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than merely 20.88% of the free cash flow producing stocks we're observing.
  • ALXN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 41.52% of tickers in our DCF set.
  • As a business, Alexion Pharmaceuticals Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than merely 0% of stocks generating free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ALXN, try PCRX, CI, INVA, SEM, and LXRX.

ALXN Latest News Stream

Event/TimeNews Detail
Loading, please wait...

ALXN Latest Social Stream

Loading social stream, please wait...

View Full ALXN Social Stream

Latest ALXN News From Around the Web

Below are the latest news stories about Alexion Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALXN as an investment opportunity.

Alexion completes acquisition of Portola Pharma; SEC charges with FCPA violations

Alexion Pharmaceuticals (ALXN) has completed its acquisition of Portola Pharmaceuticals (PTLA), through a tender offer and merger with its subsidiary, Odyssey Merger Sub Inc. (“Buyer”).The acquisition adds Factor Xa inhibitor reversal agent Andexxa, marketed as Ondexxya in Europe, to Alexion’s commercial portfolio. Portola will cease to be traded on the Nasdaq and...

Seeking Alpha | July 2, 2020

Alexion to pay $21.5 million to settle SEC foreign bribery probe

Alexion Pharmaceuticals Inc will pay nearly $21.5 million to resolve claims it improperly paid Turkish and Russian officials to secure favorable treatment for its main drug, Soliris, the U.S. Securities and Exchange Commission said Thursday.

Reuters | July 2, 2020

SEC Charges Alexion Pharmaceuticals With FCPA Violations | STL.News

SEC Charges Alexion Pharmaceuticals With FCPA Violations | STL.News | Read business news and more at STL.News.

STL.News | July 2, 2020

Why the Earnings Surprise Streak Could Continue for Alexion (ALXN)

Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Yahoo | July 2, 2020

Alexion to pay $21 million to resolve SEC charges

Shares of Alexion Pharmaceuticals Inc. were up 0.1% in trading on Thursday after the Securities and Exchange Commission said the drugmaker would pay more than $21 million to resolve charges that it paid officials in Russian and Turkey to promise its immunosuppressive drug Soliris. The company allegedly paid government officials between 2010 and 2015 to encourage prescriptions of Soliris and secure "favorable regulatory treatment" for the drug. There are also allegations that subsidiaries in Brazil and Colombia failed to main accurate records. Alexion did not admit fault or deny the SEC's findings. Soliris is Alexion's top-selling drug, bringing in about $3.9 billion in sales in 2019. Alexion's stock has gained 3.9% year-to-date, while the S&P 500 is down 3.5%.

Yahoo | July 2, 2020

Read More 'ALXN' Stories Here

ALXN Price Returns

1-mo -1.21%
3-mo 25.10%
6-mo 5.37%
1-year -13.81%
3-year -10.20%
5-year -39.70%
YTD 3.84%
2019 11.08%
2018 -18.59%
2017 -2.26%
2016 -35.86%
2015 3.09%

Continue Researching ALXN

Want to see what other sources are saying about Alexion Pharmaceuticals Inc's financials and stock price? Try the links below:

Alexion Pharmaceuticals Inc (ALXN) Stock Price | Nasdaq
Alexion Pharmaceuticals Inc (ALXN) Stock Quote, History and News - Yahoo Finance
Alexion Pharmaceuticals Inc (ALXN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0059 seconds.